GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

sonelokimab   Click here for help

GtoPdb Ligand ID: 10491

Synonyms: IL17-MS3086 | IL17MS3086 | M-1095 | M1095 | MSB-0010841 | MSB0010841 | SEQ ID 836 [WO2012156219A1]
Immunopharmacology Ligand
Compound class: Antibody
Comment: Sonelokimab (MSB0010841; M1095) is an anti-IL-17A/F single chain camelid nanobody [1]. The peptide sequence for proposed INN sonelokimab is a 100% match for SEQ ID 836 that is claimed in Merck/Ablynx patent WO2012156219A1. Sonelokimab potently binds to both IL-17A and -F and prevents IL-17R pathway activation (e.g . IL-6 production), and was designed for anti-inflammatory potential.
Bioactivity Comments
Sonelokimab binds human and cynomolgus recombinant IL-17 A and -F with no significant difference in binding affinities, and binds to marmoset versions of the cytokines, but it does not bind mouse or rat IL-17 A or -F [1]. It prevents hIL-17A/F-induced cytokine release in mouse serum [1]. Kd values in the interaction table were determined using a Myc-His tagged version of sonelokimab (known as IL17MS3091 in the patent) and are expected to be little different for the parent nanobody.
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
IL-17A Primary target of this compound Hs Antibody Binding 12.4 pKd - 1
⤷ pKd 12.4 (Kd 4x10-13 M) [1]
IL-17F Primary target of this compound Hs Antibody Binding 11.9 pKd - 1
⤷ pKd 11.9 (Kd 1.14x10-12 M) [1]